2021Äê8ÔÂ11ÈÕ£¬£¬£¬Journal of Experimental & Clinical Cancer ResearchÔÓÖ¾ÔÚÏß½ÒÏþngµç×ÓÓÎÏ·Á¥ÊôµÚÈýÒ½ÔºÎâ±ó½ÌÊÚÍŶÓÌâΪ¡°Phosphorylation of NF-¦ÊBp65 drives inflammation-mediated hepatocellular carcinogenesis and is a novel therapeutic target¡±µÄ³¤ÆªÑо¿ÂÛÎÄ£¨ÖпÆÔºÒ»Çø£©¡£¡£¡£¡£¡£
¸ÃÑо¿·¢Ã÷¸ÎÔàÂýÐÔÑ×Ö¢·´Ó³£¬£¬£¬ÓÈÆäÊÇTNF-¦Á£¬£¬£¬ÓÕ·¢¸Îϸ°ûNF-¦ÊBp65±í´ïÉϵ÷£¬£¬£¬½øÒ»²½Í¨¹ý¦Â-arrestin1½éµ¼NF-¦ÊBp65-Ser536λµãÁ×Ëữ£¬£¬£¬¼Ì¶ø¼¤»îÏÂÓÎAkt/mTORÐźÅͨ·£¬£¬£¬Ôö½øÁ˸ΰ©µÄ±¬·¢Ó뿪չ¡£¡£¡£¡£¡£¸ÃÑо¿ÊÇÎâ±ó½ÌÊÚÍŶÓÔÚNature Communications½ÒÏþÌâΪ¡°¦Â-arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling¡±¼°ÔÚAutophagy½ÒÏþÌâΪ¡°HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G1/S cycle¡±Ñо¿ÊÂÇéµÄÑÓÐø¼°ÉîÈë¡£¡£¡£¡£¡£
¸ÃÍŶÓÔÚÈ˸ΰ©×éÖ¯Ñù±¾¼°ÑªÒºÑù±¾Öмì²â·¢Ã÷NF-¦ÊBÐźÅͨ·5¸öÑÇ»ùNF-¦ÊB1¡¢¡¢¡¢NF-¦ÊB2¡¢¡¢¡¢p65(RelA)¡¢¡¢¡¢RelB¡¢¡¢¡¢c-RelÖÐÓÈÒÔp65(RelA)µÄ±í´ï¼°Á×Ëữ×îÏÔÖø¡£¡£¡£¡£¡£Æ¾Ö¤Õâ¸öÖ÷ÒªÁÙ´²·¢Ã÷£¬£¬£¬¸ÃÍŶӽøÒ»²½Í¨¹ý¸Îϸ°ûÌØÒìÇóý£¨L- NF-¦ÊBp65 KO£©Ð¡Êó¹¹½¨¸Î°©Ä£×Ó£¬£¬£¬ÓëÒ°ÉúÐÍСÊó½ÏÁ¿£¬£¬£¬L-NF-¦ÊBp65»ùÒòÇóýºó¸Î°©±¬·¢µÄÊýÄ¿¡¢¡¢¡¢Ìå»ýµÈ¾ùÏÔÖøµÍÓÚÒ°ÉúÐÍСÊ󡣡£¡£¡£¡£ÔÚDEN¡¢¡¢¡¢ËÄÂÈ»¯Ì¼¡¢¡¢¡¢TNF-¦Á¹¹½¨µÄ3ÖÖСÊó¸ÎÔàÑ×֢ģ×ÓÖУ¬£¬£¬NF-¦ÊBp65µÄ±í´ïˮƽ¼°Á×Ëữ¾ùÏÔÖøÉý¸ß£»£»£»¸Î°©Ï¸°ûʵÑé¼°ÂãÊó³ÉÁöʵÑéÖУ¬£¬£¬NF-¦ÊBÐźÅͨ·ÒÖÖÆ¼Á£¨Bay 11-7082¡¢¡¢¡¢PDTC£©ÏÔ×ÅÒÖÖÆ¸Î°©Ï¸°ûµÄÔöÖ³¼°ÒÆÖ²ÁöµÄÉú³¤¡£¡£¡£¡£¡£½øÒ»²½Í¨¹ý¦Â-arrestin1»ùÒòÇóýСÊ󡢡¢¡¢¸Î°©Ï¸°û¦Â-arrestin1»ùÒòĬȻʵÑé¡¢¡¢¡¢¼°NF-¦ÊBp65Á×ËữλµãÍ»±äʵÑéµÈ¾ÙÐÐÉîÈëµÄ»úÖÆÑо¿£¬£¬£¬·¢Ã÷¦Â-arrestin1ÏÔÖø¼¤»îNF-¦ÊBp65-Ser536λµãµÄÁ×Ëữ£¬£¬£¬µ«²¢²»¼¤»îSer276»òSer529λµãµÄÁ×Ëữ£¬£¬£¬¶øSer536λµãµÄÁ×Ëữ»î»¯ÁËÏÂÓÎAkt/mTORÐźÅͨ·£¬£¬£¬Ð§¹ûÓÕ·¢¸Îϸ°ûµÄ°©±ä¼°Ôö½ø¸Î°©µÄ¿ªÕ¹£¨Í¼1£©¡£¡£¡£¡£¡£

ͼ1£º£º£ºÔÚ¸ÎÔàÑ×֢΢ÇéÐÎÖУ¬£¬£¬TNF-¦Á¼¤»îNF-¦ÊBÐźÅͨ·£¬£¬£¬ÔÚ¦Â-arrestin1£¨ARRB1£©ÓÕµ¼ÏÂNF-¦ÊBp65ÑÇ»ùSer536λµãÁ×ËữÉϵ÷£¬£¬£¬´Ó¶ø»î»¯ÏÂÓÎAkt/mTORÐźÅͨ·£¬£¬£¬ÒÔÓÕ·¢¸Îϸ°ûµÄ°©±ä¼°Ôö½ø¸Î°©µÄ¿ªÕ¹
´ËÏîÑо¿ÎªÃ÷È·¸ÎÔàÑ×Ö¢ÇéÐÎÖÐNF-¦ÊBp65µÄÏÔÖøÉϵ÷¼°Á×ËữÔڸΰ©ÖеÄ×÷Óü°Ïà¹Ø»úÖÆÌṩÁËеĿÆÑ§ÒÀ¾Ý£¬£¬£¬Í¬Ê±Õ¹ÏÖÁ˦Â-arrestin1ÓÕµ¼NF-¦ÊBp65-Ser536Á×ËữµÄлúÖÆ£¬£¬£¬ÎªNF-¦ÊBp65¼°ÆäSer536λµãÁ×Ëữ×÷Ϊ¸Î°©·ÀÖεÄÒªº¦Ò©Îï°ÐµãÌṩÁËеÄÀíÂÛ»ù´¡¡£¡£¡£¡£¡£
Îâ±ó½ÌÊÚµÄѧÉúÐì诲©Ê¿ÓëÀ×Ò»Ãù²©Ê¿Îª´ËÎĵÄÅäºÏµÚÒ»×÷Õߣ¬£¬£¬Îâ±ó½ÌÊÚºÍÑîÒݶ¬¸±Ö÷ÈÎҽʦΪÅäºÏͨѶ×÷Õߣ¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÈýҽԺΪÂÛÎĵÚÒ»×÷Õßµ¥Î»¼°Í¨Ñ¶×÷Õßµ¥Î»¡£¡£¡£¡£¡£¸ÃÑо¿»ñµÃ¹ú¼Ò×ÔÈ»¿ÆÑ§ÖصãÏîÄ¿¼°ÃæÉÏÏîÄ¿£¨U1501224Óë82070574£©¡¢¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ðÍŶÓÏîÄ¿£¨2018B030312009£©µÄÖ§³Ö¡£¡£¡£¡£¡£
ÂÛÎÄÁ´½Ó£º£º£ºhttps://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02062-x